Recepta BioPharma is according to Ludwig and Switzerland 4-Antibody

Recepta BioPharma Biopharma, Brazilian biotechnology company dedicated to research and development of new drugs for the treatment of cancer, hit an international partnership with Switzerland 4-Antibody AG and with the Ludwig Institute for Cancer Research. The agreement will allow the Recepta BioPharma participate in the development of the newest generation of monoclonal antibodies immunomodulators for cancer treatment, said the value of José Fernando Perez, founder and President of Recepta biopharma.
"The partnership puts us on the border of the development of cancer immunotherapy", said Perez. And he added: "we are entering a competitive area because we believe that we can work quickly and efficiently." The 4-Antibody and the Ludwig Institute, which is a shareholder of Recepta biopharma, had started a partnership in this area for more than a year, work that now will be expanded with the participation of the Brazilian company.
The partnership provides for the generation and the clinical development of three monoclonal antibodies immunomodulators. Immunomodulatory antibodies are the newest generation of drugs used in cancer immunotherapy. Today the 4-Antibody and the Ludwig will make joint statement on the partnership. The Swiss company owns its own technology, already tested by Ludwig, to generate antibodies immunomodulators.
Asked about the type of cancer that could be treated with the new generation of drugs, Perez replied: "in principle [antibody], can be active for any type of cancer." The Executive did not reveal the investment in the project because there are confidentiality clauses.
By the terms of the agreement, revenue in Brazil with the project will stay with Recepta biopharma. The results earned the rest of the world will be divided between the three partners. The 4-Antibody will use its technology platform to generate the three antibodies immunomodulators against three targets that play important roles in the Suppression of the immune response in patients with cancer. These antibodies will be validated by the Ludwig Institute.
Recepta BioPharma will generate the cell lines for the production of these antibodies and, together with the Ludwig Institute, will conduct the initial clinical trials of efficacy in the treatment of cancer in Brazil and in the United States. Recepta BioPharma will also have an option for exclusive production of antibodies in Brazil.
The goal, according to Perez, is to make clinical trials with the new generation of antibodies immunomodulators in 1 phase (with restricted group of patients), in São Paulo and New York, in a period of three years. Perez acknowledged that a new capital contribution in Recepta BioPharma should be necessary.
Last year, the BNDES Par, holding arm of BNDES, and two "angel investors" (Emílio Odebrecht and Ankur Miner) pledged to provide $ 35 million in Recepta BioPharma to develop their work. At the end of the injections, the BNDESPar should stick with 16% of the share capital of the company. The remainder of the shares will be in the hands of Recepta Ludwig Institute, with 30%, angel investors, each with 20%, 12%, with Perez and Jose Barbosa Mello, Vice President of the company, with 2%.